Gsk Share Discussion Threads

[ny boy] 08/11/2017 10:55

One to buy on decent pull backs and hold for a few years collecting quarterly divis. Imho

[tradermichael] 08/11/2017 07:48

GSK submits US regulatory application for mepolizumab in eosinophilic chronic obstructive pulmonary disease (COPD)

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced the submission of a supplemental Biologics License Application (sBLA) to the United States Food and Drug Administration (FDA), seeking approval of mepolizumab, an interleukin-5 (IL-5) antagonist, as an add-on to maintenance treatment for patients who have chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype.

The submission includes phase III data from the previously reported(1,2) METREX and METREO studies.

Mepolizumab is not approved anywhere in the world for COPD. The submission to the FDA is the first to a regulatory authority for mepolizumab for COPD. Regulatory filings in other countries are planned during the course of 2017 and 2018.

[supermarky] 07/11/2017 20:01

Bought a few today for divi and value

[jadeticl3] 07/11/2017 16:05

The Analysts are all forecasting rain for this afternoon because it was raining this morning. This is a change from yesterday when they all forecast sunshine for today because it was sunny yesterday. However they are confident that they are correct today as this is a forward-looking science!!!

[tradermichael] 07/11/2017 15:08

I'm staying for the end game. At this rate there will be a bid..... ;0)

[che7win] 07/11/2017 15:04

A strong move up, maybe US buyers reversing their shorts.

[bracke] 07/11/2017 14:39

Testing support again.


GSK DAILY

[pugugly] 07/11/2017 14:39

Ex-dividend date Thursday 9 November 2017 So could fall another 19p tomorrow. Could therefore possibly see the dreaded £13.00 come Friday - T/O target then ??

[wi1l] 07/11/2017 14:29

That's the dividend taken care of today. And whats going to happen Thurs? more of the same most likely, there doesn't seem to be an end to this.

[romeike] 07/11/2017 14:25

@Trader Michael Jumping ship or was he pushed? I suggest he was pushed, and quite firmly too.

[tradermichael] 07/11/2017 14:20

If this CEO was a Premier League football club manager, she would have been sacked by now after this share price debacle .....;0)

[philanderer] 07/11/2017 10:17

7th nov Morgan Stanley 'underweight' tp 1450p cut from 1600p

[gbh2] 07/11/2017 10:02

Not showing much enthusiasm for the dividend!

[cyberian] 06/11/2017 22:13

Interesting post from a leading analyst in the US who suggests that recent portfolio activity by Glaxo indicate that the British Drug maker may be preparing to initiate a lawsuit claiming that GILEAD experimental HIV Bictegravir drug infringes on its patents.

[philanderer] 06/11/2017 12:59

Market report:

...Elsewhere in the top flight, AstraZeneca got a much-needed vote of confidence after it was picked by Investec as its preferred stock among UK large-cap pharmas.

Analyst Andrew Whitney (Investec) said: “We continue to see a rich product pipeline that can give multiple clinical and regulatory data points over the next 12 months.”

He has a Buy rating and a price target of 5500p, although the stock still shed 11p to 5169p today.

He is more cautious about Astra’s rival GlaxoSmithKline. He downgraded that to Hold and cut earnings estimates, adding that there were fewer catalysts to drive earnings upgrades. Shares were flat at 1360.79p.

[essentialinvestor] 04/11/2017 10:51

With the XD on Thursday, further share price weakness early next week brings £13
or a dip below £13 in to focus. Hopefully not the case.

[dr biotech] 04/11/2017 08:43

TM unfortunately that also shows that if you held GSK for the long term it wouldn’t have been a great investment. But I feeel at this level it’s got to be a decent 2 to 3 year punt

[ny boy] 04/11/2017 08:18

Bargain for savvy long term investors, will check back in before the end of the year on recovery progress, divi will do for now, as it does every quarter enjoy!

[tradermichael] 04/11/2017 08:11

20 years ago, in September 1997, the GSK share price rose from today's price to 2068p one year later ........

[cyberian] 03/11/2017 22:34

OK but equiv. at 1383p at official close on over 4 million ADR trades...not out of the woods yet but a better trend in sight, perhaps.

[essentialinvestor] 03/11/2017 20:31

Ah moves tend to be volatile, asuume on lowish volume,
the GSK ADR frequently bobs up or down after hrs.

[cyberian] 03/11/2017 20:23

WS after hours trading has GSK at equiv. 1388p on above average volume.

[essentialinvestor] 03/11/2017 12:22

Vallance is not rated by many comments I have read over the years, whether this is justified or not..

[cyberian] 03/11/2017 11:43

Agree Luke Miels was a big gain, and needed to sharpen-up on improved commercial and faster application in the pharma sector. Quite a productive and positive development for GSK, and the changes should be seen as constructive and welcome by the Institutions...certainly not a negative.

[essentialinvestor] 03/11/2017 11:34

Cyberian, I would much prefer Mr Miles in the top R&D job.
He played a major role in the rejuvenation of AZN and their oncology pipeline,
so little wonder Emma poached him.

The AZN CEO was reportedly furious at Lukes departure.